Related Experiment Video
Updated: Mar 12, 2026
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis
A Kollár1, R L Jones2, S Stacchiotti3
1a Sarcoma Unit, Department of Medical Oncology , University Hospital of Bern , Bern , Switzerland.
Background:
Pazopanib is a multitargeted tyrosine kinase inhibitor approved for the treatment of patients with selective subtypes of advanced soft tissue sarcoma (STS) who have previously received standard chemotherapy including anthracyclines. Data on the efficacy in vascular sarcomas are limited. The main objective of this study was to investigate the activity of pazopanib in vascular sarcomas.
Patients And Methods:
A retrospective study of patients with advanced vascular sarcomas, including angiosarcoma (AS), epithelioid hemangioendothelioma (HE) and intimal sarcoma (IS) treated with pazopanib in real life practice at EORTC centers as well as patients treated within the EORTC phase II and III clinical trials (62043/62072) was performed. Patient and tumor characteristics were collected. Response was assessed according to RECIST 1.1. and survival analysis was performed.
Results:
Fifty-two patients were identified, 40 (76.9%), 10 (19.2%) and two (3.8%) with AS, HE and IS, respectively. The response rate was eight (20%), two (20%) and two (100%) in the AS, HE and IS subtypes, respectively. There was no significant difference in response rate between cutaneous and non-cutaneous AS and similarly between radiation-associated and non-radiation-associated AS. Median progression-free survival (PFS) and median overall survival (OS; from commencing pazopanib) were three months (95% CI 2.1-4.4) and 9.9 months (95% CI 6.5-11.3) in AS, respectively.
Conclusion:
The activity of pazopanib in AS is comparable to its reported activity in other STS subtypes. In this study, the activity of pazopanib was similar in cutaneous/non-cutaneous and in radiation/non-radiation-associated AS. In addition, pazopanib showed promising activity in HE and IS, worthy of further evaluation.
Insights
Pazopanib demonstrated comparable activity in advanced angiosarcoma (AS) to other soft tissue sarcoma (STS) subtypes. This study also found pazopanib showed promising efficacy in epithelioid hemangioendothelioma (HE) and intimal sarcoma (IS).
Area of Science:
- Oncology
- Medical Oncology
- Sarcoma Research
Background:
- Pazopanib is a tyrosine kinase inhibitor approved for advanced soft tissue sarcoma (STS) after chemotherapy.
- Limited data exist on pazopanib's efficacy in vascular sarcomas.
- This study aimed to evaluate pazopanib's activity in vascular sarcomas.
Purpose of the Study:
- To investigate the clinical activity of pazopanib in patients with advanced vascular sarcomas.
- To assess response rates and survival outcomes in different subtypes of vascular sarcoma treated with pazopanib.
Main Methods:
- Retrospective analysis of 52 patients with advanced vascular sarcomas (angiosarcoma, epithelioid hemangioendothelioma, intimal sarcoma).
- Patients received pazopanib in real-world practice or clinical trials.
- Response evaluated by RECIST 1.1; survival analysis performed.
Main Results:
- Pazopanib showed a 20% response rate in angiosarcoma (AS), 20% in epithelioid hemangioendothelioma (HE), and 100% in intimal sarcoma (IS).
- Median progression-free survival (PFS) was 3 months and median overall survival (OS) was 9.9 months for AS.
- No significant difference in AS response based on location or radiation history.
Conclusions:
- Pazopanib's activity in AS is comparable to other STS subtypes.
- Pazopanib demonstrated promising activity in HE and IS, warranting further investigation.
- Treatment outcomes were consistent across different angiosarcoma classifications.
Related Concept Videos
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:21Cancer Survival Analysis